Latest News

Ultomiris (ravulizumab) now publicly reimbursed in gMG

April 7, 2026  

ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease

PrUltomiris® (ravulizumab) now publicly reimbursed for adult anti-AchR-antibody-positive generalized myasthenia gravis in Ontario, Alberta, Nova Scotia, Saskatchewan, Newfoundland and Labrador, and NIHB

Alexion, AstraZeneca Rare Disease is pleased to announce that as of March 26, 2026, ravulizumab (Ultomiris) is listed in Ontario through the Exceptional Access Program (EAP) for the treatment of adult patients with anti-anticholinergic receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). Read More

CLINICAL CASES IN NEUROLOGY: A 51 y.o. with suspected transverse myelitis

March 18, 2026  

Click here to watch Dr. Dalia Rotstein discuss the case and your responses to the quick poll.

A 51-year-old woman presents with lower extremity weakness and numbness which began 24 hours ago and gradually ascended up to her mid-chest. She could not ambulate for the last 12 hours, and it is more difficult to pass urine. She has no history of recent infectious symptoms or travel. Read More

Ultomiris (ravulizumab) now publicly reimbursed in NMOSD

March 4, 2026  

ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease

PrUltomiris® (ravulizumab) now publicly reimbursed for adult anti-AQP4 antibody-positive NMOSD in Ontario, Quebec, Alberta, Nova Scotia, Saskatchewan, and NIHB

Alexion, AstraZeneca Rare Disease is pleased to announce that as of January 20th, 2026, ravulizumab (Ultomiris) is now listed on the Ontario Drug Benefit program for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disease (NMOSD). Read More